Epocrates, which provides mobile drug reference tools to healthcare professionals, announced terms for its IPO on Thursday. The San Mateo, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13-$15. At the mid-point of the proposed range, Epocrates will command a market value of $343 million. Epocrates, which was founded in 1998 and booked $101 million in sales for the 12 months ended September 30, plans to list on the NASDAQ under the symbol EPOC. J.P. Morgan and Piper Jaffray are the lead underwriters on the deal, which is expected to price during the week of January 31.
